September 2020 Briefing – Diabetes & Endocrinology
Here are what the editors at HealthDay consider to be the most important developments in Diabetes & Endocrinology for September 2020. This roundup includes...
Pancreas Size, Shape Restored With Remission of T2DM
Responders had increase in pancreas volume, normalization of irregular pancreas borders
Hospital Admissions Not Related to COVID-19 Fell in Early 2020
From February to April 2020, drop >20 percent observed for all primary admission diagnoses
Proton Pump Inhibitor Use Linked to Increased T2DM Risk
Type 2 diabetes risk increased with increasing length of PPI use, particularly use for more than two years
Exposure to Maternal Gestational Diabetes Tied to Higher CVD Risk
Increased risk for cardiovascular disease observed in offspring for up to 35 years of follow-up
Private Health Plans Pay Hospitals 247 Percent of Medicare
Relative prices average 231, 267 percent of what Medicare would pay for inpatient, outpatient services
Diagnoses of Common Conditions Declined in March to May 2020
Common mental health diagnoses reduced 50 percent; similar drops seen in circulatory system diseases, T2DM
Once-Weekly Insulin Icodec Promising for Type 2 Diabetes
In phase 2 study, glucose-lowering efficacy, safety profile similar to once-daily insulin glargine U100
Rheumatoid Arthritis Linked to Higher Risk for Type 2 Diabetes
RA linked to increased risk for developing diabetes; association remained in sensitivity analysis
Heavy Sugar-Sweetened Drink Intake Decreasing Overall in U.S.
Heavy SSB intake up for adults ≥60 years; no change seen for those age 40 to 59 years, non-Mexican Hispanics
